News
-
-
PRESS RELEASE
aap confirms Rubino Di Girolamo as CEO through the end of 2028; COO Agnieszka Mierzejewska will leave the company at the end of the year
CEO Rubino Di Girolamo extends contract at aap Implantate AG until 2028; COO Agnieszka Mierzejewska to leave in 2025. Company focuses on new antibacterial technology and strategic realignment -
-
PRESS RELEASE
aap Implantate AG closes the first half of the year with sales of € 6.2 million; clinical trial nears positive conclusion
aap Implantate AG reports €6.2 million sales in the first half of 2025, with clinical trial near positive conclusion. Regional growth in EMEA, strong performance in APAC, US tariff impact mitigated -
-
-
-
PRESS RELEASE
aap Implantate AG: Full admission of all previously unadmitted shares, introduction to stock exchange trading and termination of lock-up agreements
aap Implantate AG announces full admission of previously unadmitted shares to the Frankfurt Stock Exchange's regulated market, along with the termination of lock-up agreements -
-
PRESS RELEASE
aap Implantate AG publishes final audited consolidated financial statements 2024 - confirmation of strong operational improvement
aap Implantate AG publishes final audited consolidated financial statements 2024, confirming strong operational improvement. The company achieved a significant increase in Group EBITDA
